These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20378715)

  • 1. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
    Masferrer JL; Zweifel BS; Hardy M; Anderson GD; Dufield D; Cortes-Burgos L; Pufahl RA; Graneto M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):294-301. PubMed ID: 20378715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
    Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
    Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
    Cortes-Burgos LA; Zweifel BS; Settle SL; Pufahl RA; Anderson GD; Hardy MM; Weir DE; Hu G; Happa FA; Stewart Z; Muthian S; Graneto MJ; Masferrer JL
    Eur J Pharmacol; 2009 Sep; 617(1-3):59-67. PubMed ID: 19580807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
    Horrillo R; Planagumà A; González-Périz A; Ferré N; Titos E; Miquel R; López-Parra M; Masferrer JL; Arroyo V; Clària J
    J Pharmacol Exp Ther; 2007 Dec; 323(3):778-86. PubMed ID: 17766677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6138-41. PubMed ID: 18945614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
    Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
    J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of (2-fluoro-benzyl)-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine (KRH-102140) as an orally active 5-lipoxygenase inhibitor with activity in murine inflammation models.
    Cho YS; Song JS; Huh JY; Kim CH; Gong YD; Cheon HG
    Pharmacology; 2011; 87(1-2):49-55. PubMed ID: 21212714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors.
    Cusan C; Spalluto G; Prato M; Adams M; Bodensieck A; Bauer R; Tubaro A; Bernardi P; Da Ros T
    Farmaco; 2005 Apr; 60(4):327-32. PubMed ID: 15848208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast.
    Ramires R; Caiaffa MF; Tursi A; Haeggström JZ; Macchia L
    Biochem Biophys Res Commun; 2004 Nov; 324(2):815-21. PubMed ID: 15474500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH; Rao PN; Knaus EE
    Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
    Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
    J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
    Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
    Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
    Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
    Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
    Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a fluorescence-based enzyme assay of human 5-lipoxygenase.
    Pufahl RA; Kasten TP; Hills R; Gierse JK; Reitz BA; Weinberg RA; Masferrer JL
    Anal Biochem; 2007 May; 364(2):204-12. PubMed ID: 17376394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
    Singh VP; Patil CS; Kulkarni SK
    Indian J Exp Biol; 2004 Jul; 42(7):667-73. PubMed ID: 15339030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.